| Effect | Increase |
| Trial Design | Double blind |
| Trial Length | 1-7 Days |
| Number of Subjects | 36 |
| Sex | Both Genders |
| Age Range | 18-29, 30-44 |
Two doses of 80mg EGb-761 (24 and 12 hours prior to ascension) followed by ingestion of EGb-761 twice daily during the trip was able to severely reduce the occurrence of AMS with a potency greater than the reference drug acetazolamide and improved oxygen carrying capacity of the blood.
